摘要
临床常见的炎性皮肤病,如,银屑病、特应性皮炎和接触性皮炎等,其典型特征是T淋巴细胞浸润为主的皮肤炎症。趋化因子CCL27主要由皮肤角质形成细胞产生,其惟一受体是CCRl0。CCL27和CCRl0的相互作用,诱导皮肤记忆T细胞向局部皮肤的聚集,形成并维持了各种炎性皮损,因而已成为药物研究的新靶点。尽管目前尚无真正的临床药物可用,但体外研究和动物实验的良好效果为炎性皮肤病的治疗开启了一扇新的大门。
Common inflammatory skin diseases such as psoriasis, atopic dermatitis and contact dermatitis are characterized by typical skin inflammation represented by infiltrating T lymphocytes. Chemokine CCL27, with CCR10 as its only receptor, is mainly produced by keratinocytes. Since CCL27-CCR10 interactions can induce skin memory T cells to migrate to the local skin, thus to form and maintain a variety of inflammatory skin lesions, they have become a new target for drug development. Although there has been no practical clinical medicine, the favorable outcomes in studies in vivo and in vitro do open a new door for the treatment of inflammatory skin diseases with anti-CCL27 antibodies or CCR10 antagonists.
出处
《国际皮肤性病学杂志》
2012年第6期396-399,共4页
International Journal of Dermatology and Venereology